KJ-C2113

KJ-C2113 is a preclinical or IND-enabling stage chimeric antigen receptor (CAR) T-cell therapy candidate being developed by CARsgen Therapeutics. First disclosed in the company's 2021 annual report, KJ-C2113 is part of a pipeline of next-generation cell therapies aimed at treating various cancers. While the specific biological target and primary indication remain proprietary and have not been publicly identified, the candidate likely leverages CARsgen's specialized technology platforms, such as CycloCAR or LADAR, which are designed to enhance the efficacy, persistence, and safety of CAR-T cells within the immunosuppressive tumor microenvironment.